US5151444B1
(en)
*
|
1987-09-18 |
1999-07-06 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
US5212200A
(en)
*
|
1987-09-18 |
1993-05-18 |
R-Tech Ueno, Ltd. |
Ocular hypotensive agents
|
US5236907A
(en)
*
|
1988-10-01 |
1993-08-17 |
R-Tech Ueno Ltd. |
Ocular hypotensive agents
|
US5166178B1
(en)
*
|
1987-09-18 |
1998-07-21 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
US6420422B1
(en)
|
1987-09-18 |
2002-07-16 |
Sucampo Pharmaceuticals, Inc. |
Ocular hypotensive agents
|
US5565492A
(en)
*
|
1988-07-18 |
1996-10-15 |
Alcon Laboratories, Inc. |
Prostaglandin combinations in glaucoma therapy
|
US5296504A
(en)
*
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5321128A
(en)
*
|
1988-09-06 |
1994-06-14 |
Kabi Pharmacia Ab |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US6187813B1
(en)
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
ES2193901T1
(en)
*
|
1988-09-06 |
2003-11-16 |
Pharmacia Ab |
PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION.
|
US5194429A
(en)
*
|
1988-10-01 |
1993-03-16 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Ocular hypotensive agents
|
HU212570B
(en)
*
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
US5223537A
(en)
*
|
1991-07-23 |
1993-06-29 |
Kabi Pharmacia Ab |
Method and composition for treatment of gastric and duodenal disorders
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US6602900B2
(en)
*
|
1992-09-21 |
2003-08-05 |
Allergan, Inc. |
Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5688819A
(en)
*
|
1992-09-21 |
1997-11-18 |
Allergan |
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5834498A
(en)
*
|
1992-09-21 |
1998-11-10 |
Allergan |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5352708A
(en)
*
|
1992-09-21 |
1994-10-04 |
Allergan, Inc. |
Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5468778A
(en)
*
|
1992-09-24 |
1995-11-21 |
Allergan, Inc. |
Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
|
ES2105333T3
(en)
*
|
1992-10-13 |
1997-10-16 |
Alcon Lab Inc |
COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA.
|
US5332730A
(en)
*
|
1992-10-16 |
1994-07-26 |
Allergan, Inc. |
Azido derivatives of cyclopentane heptanoic or heptenoic acid
|
US5385945A
(en)
*
|
1992-10-21 |
1995-01-31 |
Allergan, Inc. |
7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
|
US5328933A
(en)
*
|
1992-10-28 |
1994-07-12 |
Allergan, Inc. |
Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
|
US5312842A
(en)
*
|
1992-10-30 |
1994-05-17 |
Allergan, Inc. |
Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
|
US6184250B1
(en)
*
|
1993-08-03 |
2001-02-06 |
Alcon Laboratories, Inc. |
Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
|
US5510383A
(en)
*
|
1993-08-03 |
1996-04-23 |
Alcon Laboratories, Inc. |
Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
|
US5387608A
(en)
*
|
1993-08-17 |
1995-02-07 |
Allergan, Inc. |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
|
US5476872A
(en)
*
|
1993-10-18 |
1995-12-19 |
Allergan, Inc. |
1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
|
US5486540A
(en)
*
|
1993-10-28 |
1996-01-23 |
Allergan, Inc. |
Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
|
US5721273A
(en)
*
|
1993-12-15 |
1998-02-24 |
Alcon Laboratories, Inc. |
Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
|
US5627209A
(en)
*
|
1993-12-15 |
1997-05-06 |
Alcon Laboratories, Inc. |
Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
|
US6462077B1
(en)
|
1993-12-28 |
2002-10-08 |
Allergan, Inc. |
Thromboxane ligands without blood clotting side effects
|
US5650431A
(en)
*
|
1993-12-28 |
1997-07-22 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5741812A
(en)
*
|
1993-12-28 |
1998-04-21 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5416106A
(en)
*
|
1993-12-28 |
1995-05-16 |
Allergan, Inc. |
7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
|
US5545665A
(en)
*
|
1993-12-28 |
1996-08-13 |
Allergan |
Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
|
US5462968A
(en)
*
|
1994-01-19 |
1995-10-31 |
Allergan, Inc. |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
US5516796A
(en)
*
|
1994-03-24 |
1996-05-14 |
Kabi Pharmacia Ab |
Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
|
SE9401087D0
(en)
*
|
1994-03-31 |
1994-03-31 |
Pharmacia Ab |
New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
SE9403158D0
(en)
*
|
1994-09-21 |
1994-09-21 |
Pharmacia Ab |
New use of prostaglandins
|
US5807892A
(en)
*
|
1994-09-30 |
1998-09-15 |
Alcon Laboratories, Inc. |
Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
|
US5698733A
(en)
*
|
1994-09-30 |
1997-12-16 |
Alcon Laboratories, Inc. |
Use of 9-deoxy prostaglandin derivatives to treat glaucoma
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
CA2221110C
(en)
*
|
1995-05-18 |
2009-08-04 |
Allergan |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
|
AU7672096A
(en)
|
1995-06-07 |
1998-06-03 |
Alcon Laboratories, Inc. |
Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
|
US5698598A
(en)
*
|
1995-08-04 |
1997-12-16 |
Allergan |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
WO1997023225A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Alcon Laboratories, Inc. |
Combinations of dp and fp type prostaglandins for lowering iop
|
US5700835A
(en)
*
|
1995-12-22 |
1997-12-23 |
Alcon Laboratories, Inc. |
3-Oxa-D-prostaglandins for lowering IOP
|
US5658897A
(en)
*
|
1996-04-08 |
1997-08-19 |
Allergan |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
|
DE69714274T3
(en)
†
|
1996-09-17 |
2006-06-01 |
Asahi Glass Co., Ltd. |
FLUORATED PROSTAGLANDINE DERIVATIVES AND MEDICAMENTS
|
US6353000B1
(en)
*
|
1996-11-12 |
2002-03-05 |
Alcon Laboratories, Inc. |
11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
|
EP0944593A2
(en)
*
|
1996-11-12 |
1999-09-29 |
Alcon Laboratories, Inc. |
$i(CIS)-$g(D)?4 ANALOGS OF PROSTAGLANDINS AS OCULAR HYPOTENSIVES
|
WO1998033497A1
(en)
|
1997-02-04 |
1998-08-06 |
Johnstone Murray A |
Method of enhancing hair growth
|
EP0968183A2
(en)
|
1997-03-07 |
2000-01-05 |
Alcon Laboratories, Inc. |
13-thia prostaglandins for use in glaucoma therapy
|
US6770675B2
(en)
|
1997-03-17 |
2004-08-03 |
Novartis Ag |
Compositions and methods for reducing ocular hypertension
|
CA2293325C
(en)
*
|
1997-05-09 |
2008-09-02 |
The Mount Sinai School Of Medicine Of The City University Of New York |
8-iso-prostaglandins for glaucoma therapy
|
WO1999012895A1
(en)
*
|
1997-09-09 |
1999-03-18 |
The Procter & Gamble Company |
Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
|
WO1999012898A1
(en)
*
|
1997-09-09 |
1999-03-18 |
The Procter & Gamble Company |
Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
|
CA2274708A1
(en)
*
|
1997-10-13 |
1999-04-22 |
R-Tech Ueno, Ltd. |
Remedial composition for intraocular hypertension or glaucoma
|
WO1999018970A1
(en)
*
|
1997-10-14 |
1999-04-22 |
Senju Pharmaceutical Co., Ltd. |
Preventives and remedies for ophthalmic circulatory disturbance
|
US6646001B2
(en)
|
1997-12-19 |
2003-11-11 |
Alcon Manufacturing, Ltd. |
Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
|
US6066671A
(en)
|
1997-12-19 |
2000-05-23 |
Alcon Laboratories, Inc. |
Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
|
US6492417B1
(en)
|
1997-12-22 |
2002-12-10 |
Alcon Manufacturing, Ltd. |
11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
|
US6441033B1
(en)
|
1997-12-22 |
2002-08-27 |
Alcon Manufacturing, Ltd. |
11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
|
AU749796B2
(en)
|
1998-03-31 |
2002-07-04 |
Duke University |
C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
US6160013A
(en)
*
|
1998-12-17 |
2000-12-12 |
Alcon Laboratories, Inc. |
14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
|
SE9900672D0
(en)
*
|
1999-02-25 |
1999-02-25 |
Synphora Ab |
Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
|
HUP0200258A2
(en)
|
1999-03-05 |
2002-05-29 |
The Procter & Gamble Co. |
C16 unsaturated fp-selective prostaglandins analogs, pharmaceutical compositions containing them and their use
|
US6894175B1
(en)
*
|
1999-08-04 |
2005-05-17 |
The Procter & Gamble Company |
2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
|
TWI290470B
(en)
|
1999-12-01 |
2007-12-01 |
Sankyo Co |
The composition for treating glaucoma
|
AU2001241143B2
(en)
*
|
2000-03-16 |
2005-08-25 |
Sucampo Ag |
Composition for use in treatment of ocular hypertension and glaucoma
|
US6458836B1
(en)
|
2000-03-16 |
2002-10-01 |
Sucampo, A.G. |
Treatment of ocular hypertension and glaucoma
|
US6927233B1
(en)
|
2000-03-17 |
2005-08-09 |
Alcon, Inc. |
5ht2 agonists for controlling IOP and treating glaucoma
|
US6806285B1
(en)
|
2000-03-17 |
2004-10-19 |
Alcon, Inc. |
5-Hydroxyl indole derivatives for treating glaucoma
|
US20030119846A1
(en)
*
|
2000-03-17 |
2003-06-26 |
Collier Jr Robert J. |
Compounds with 5-ht activity useful for controlling visual field loss
|
US7005443B1
(en)
|
2000-03-17 |
2006-02-28 |
Alcon, Inc. |
5-Hydroxy indazole derivatives for treating glaucoma
|
AU2001219185A1
(en)
|
2000-03-17 |
2001-10-03 |
Alcon, Inc. |
2-acylaminobenzimidazole derivatives for treating glaucoma
|
US6956036B1
(en)
|
2000-03-17 |
2005-10-18 |
Alcon, Inc. |
6-hydroxy-indazole derivatives for treating glaucoma
|
US7012090B1
(en)
|
2000-03-17 |
2006-03-14 |
Alcon, Inc. |
Pyranoindoles for treating glaucoma
|
US20020013294A1
(en)
|
2000-03-31 |
2002-01-31 |
Delong Mitchell Anthony |
Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
|
US20020172693A1
(en)
*
|
2000-03-31 |
2002-11-21 |
Delong Michell Anthony |
Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
|
US20020037914A1
(en)
|
2000-03-31 |
2002-03-28 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
|
US20020146439A1
(en)
*
|
2000-03-31 |
2002-10-10 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
|
AU2001261019A1
(en)
*
|
2000-05-15 |
2001-11-26 |
Pharmacia And Upjohn Company |
Process and intermediates to prepare latanoprost
|
GB0012249D0
(en)
*
|
2000-05-19 |
2000-07-12 |
Chirotech Technology Ltd |
Process for the preparation of 11-oxaprostaglandins
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
PE20020146A1
(en)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
|
US20020035148A1
(en)
|
2000-07-20 |
2002-03-21 |
Ryuji Ueno |
Treatment of ocular hypertension
|
US6586462B2
(en)
|
2000-10-20 |
2003-07-01 |
Allergan, Inc. |
ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
|
US6376533B1
(en)
*
|
2000-10-20 |
2002-04-23 |
Allergan Sales, Inc. |
Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
|
WO2004098807A1
(en)
*
|
2000-11-21 |
2004-11-18 |
Barsplice Products, Inc. |
Method of making steel couplers for joining concrete reinforcing bars
|
ES2250504T3
(en)
|
2000-11-29 |
2006-04-16 |
Allergan Inc. |
PREVENTION OF REJECTION OF GRAFT IN THE EYE.
|
EP1418903A2
(en)
*
|
2001-04-23 |
2004-05-19 |
The Board of Regents of the University of Texas System |
Prostanoids augment ocular drug penetration
|
KR100437873B1
(en)
*
|
2001-05-08 |
2004-06-26 |
연성정밀화학(주) |
Process for preparing prostaglandin derivatives and stereospecific starting material thereof
|
US20030212107A1
(en)
*
|
2001-05-10 |
2003-11-13 |
Kapin Michael A. |
R-reliprodil for treating glaucoma
|
GB0112699D0
(en)
|
2001-05-24 |
2001-07-18 |
Resolution Chemicals Ltd |
Process for the preparation of prostglandins and analogues thereof
|
TWI298257B
(en)
|
2001-05-31 |
2008-07-01 |
Allergan Inc |
Hypotensive lipid and timolol compositions and methods of using same
|
EP1392658A4
(en)
*
|
2001-06-01 |
2004-10-13 |
Alcon Inc |
Novel fused indazoles and indoles and their use for the treatment of glaucoma
|
CN1512879A
(en)
*
|
2001-06-01 |
2004-07-14 |
�Ƹ��� |
Novel arylaminopropane analogues and their use for treatment of glaucoma
|
JP2004535418A
(en)
*
|
2001-06-01 |
2004-11-25 |
アルコン,インコーポレイテッド |
Pyranoindazole and its use in treating glaucoma
|
US7872045B2
(en)
*
|
2001-06-14 |
2011-01-18 |
Allergan, Inc. |
Combination therapy for glaucoma treatment
|
US20030027853A1
(en)
*
|
2001-06-14 |
2003-02-06 |
Allergan Sales, Inc. |
3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
|
US20050222094A1
(en)
*
|
2001-06-14 |
2005-10-06 |
Burk Robert M |
Treatment of inflammatory bowel disease
|
US6713268B2
(en)
*
|
2001-06-26 |
2004-03-30 |
Allergan, Inc. |
Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
|
KR100581647B1
(en)
|
2001-07-17 |
2006-05-22 |
파마시아 앤드 업존 캄파니 엘엘씨 |
Process and Intermediates to Prepare Latanoprost
|
US20030187071A1
(en)
*
|
2001-07-17 |
2003-10-02 |
Henegar Kevin E. |
Process and intermediates to prepare latanoprost
|
US20030060511A1
(en)
*
|
2001-08-23 |
2003-03-27 |
Sucampo Ag |
Method for treatment of ocular hypertension and glaucoma
|
US6884816B2
(en)
|
2001-08-31 |
2005-04-26 |
Alcon, Inc. |
Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
|
US20040254230A1
(en)
*
|
2001-12-03 |
2004-12-16 |
Ogidigben Miller J. |
Method for treating ocular hypertension
|
TW200305424A
(en)
|
2002-01-29 |
2003-11-01 |
Santen Pharmaceutical Co Ltd |
Glaucoma-treating agent comprising bunazosin and prostaglandin
|
US9216183B2
(en)
|
2002-02-04 |
2015-12-22 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US7351404B2
(en)
|
2002-02-04 |
2008-04-01 |
Allergan, Inc. |
Method of enhancing hair growth
|
US8758733B2
(en)
|
2002-02-04 |
2014-06-24 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US20040110776A1
(en)
*
|
2002-02-22 |
2004-06-10 |
Iok-Hou Pang |
Use of propentofylline to control intraocular pressure
|
US20050239872A1
(en)
|
2002-06-06 |
2005-10-27 |
Xavier Billot |
1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
|
US20060258726A1
(en)
*
|
2002-06-06 |
2006-11-16 |
Xavier Billot |
1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
|
US6864282B2
(en)
|
2002-08-05 |
2005-03-08 |
Allergan, Inc. |
9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
|
US20040076678A1
(en)
*
|
2002-08-21 |
2004-04-22 |
Sucampo Ag |
Opthalmic solution
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
JP2006504679A
(en)
*
|
2002-08-28 |
2006-02-09 |
メルク フロスト カナダ アンド カンパニー |
Oxazolidin-2-one and thiazolidine-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
|
US20050245509A1
(en)
*
|
2002-08-29 |
2005-11-03 |
Santen Pharmacecutical Co., Ltd. |
Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
|
BR0314419A
(en)
*
|
2002-08-30 |
2005-07-19 |
Alcon Inc |
Substituted 5-chroman-5-yl-ethylamine compounds, their use and pharmaceutical composition including
|
KR101182496B1
(en)
|
2002-09-09 |
2012-09-12 |
산텐 세이야꾸 가부시키가이샤 |
Transparent eye drops containing latanoprost
|
US7074827B2
(en)
*
|
2002-10-24 |
2006-07-11 |
Sucampo Ag (Usa) Inc. |
Method for treating ocular hypertension and glaucoma
|
US20060167081A1
(en)
*
|
2002-10-25 |
2006-07-27 |
Xavier Billot |
Ep4 receptor agonists
|
EP1581503A4
(en)
*
|
2002-11-08 |
2007-07-25 |
Merck & Co Inc |
Ophthalmic compositions for treating ocular hypertension
|
US7196082B2
(en)
*
|
2002-11-08 |
2007-03-27 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
EP1562592A4
(en)
*
|
2002-11-12 |
2009-01-21 |
Alcon Inc |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
US20080004311A1
(en)
*
|
2002-11-12 |
2008-01-03 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
WO2004045644A1
(en)
|
2002-11-18 |
2004-06-03 |
Santen Pharmaceutical Co., Ltd. |
REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND β-BLOCKER
|
US7053085B2
(en)
|
2003-03-26 |
2006-05-30 |
Merck & Co. Inc. |
EP4 receptor agonist, compositions and methods thereof
|
JP2006511556A
(en)
*
|
2002-12-13 |
2006-04-06 |
アルコン,インコーポレイテッド |
Novel benzopyran analogs and their use for the treatment of glaucoma
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
AR043161A1
(en)
*
|
2003-02-14 |
2005-07-20 |
Sucampo Pharmaceuticals Inc |
OPHTHALM COMPOSITION TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
|
US20060148805A1
(en)
*
|
2003-07-01 |
2006-07-06 |
Meng Hsin Chen |
Opthalmic compositions for treating ocular hypertension
|
EP1661573B1
(en)
*
|
2003-08-21 |
2013-09-25 |
Sucampo AG |
Ophtalmic composition comprising unoprostone ispopropyl ester and a viscosity agent
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US7576122B2
(en)
*
|
2003-09-02 |
2009-08-18 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
AU2004271978B2
(en)
*
|
2003-09-04 |
2009-02-05 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
CN102558231B
(en)
*
|
2003-09-04 |
2015-05-27 |
默沙东公司 |
Ophthalmic compositions for treating ocular hypertension
|
US20050058730A1
(en)
*
|
2003-09-15 |
2005-03-17 |
Xushan Wan |
Compositions and methods for preventing or treating eyestrain
|
EP1675588A4
(en)
*
|
2003-10-22 |
2010-04-21 |
Univ Rochester |
Use of peroxisome proliferator-activated receptor gamma (ppar gamma) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
|
DE602004023106D1
(en)
*
|
2003-11-07 |
2009-10-22 |
Senju Pharma Co |
PHARMACEUTICAL COMPOSITION WITH PROSTAGLANDIN
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
US7476687B2
(en)
*
|
2003-11-26 |
2009-01-13 |
Alcon, Inc. |
Substituted furo[2,3-g]indazoles for the treatment of glaucoma
|
US7338972B1
(en)
|
2003-12-15 |
2008-03-04 |
Alcon, Inc. |
Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
|
US7129257B1
(en)
|
2003-12-15 |
2006-10-31 |
Alcon, Inc. |
Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
|
AR046890A1
(en)
*
|
2003-12-15 |
2005-12-28 |
Alcon Inc |
[1,4] OXAZINO [2,3-G] SUBSTITUTED INDAZOLS FOR THE TREATMENT OF GLAUCOMA.
|
MXPA06007678A
(en)
|
2004-01-05 |
2006-09-01 |
Nicox Sa |
Prostaglandin nitrooxyderivatives.
|
CA2553381C
(en)
|
2004-01-20 |
2011-03-22 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
CN1946384B
(en)
*
|
2004-04-26 |
2011-04-20 |
爱尔康公司 |
Statins for the treatment of ocular hypertension and glaucoma
|
US8591885B2
(en)
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244458A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
JP2008507521A
(en)
|
2004-07-20 |
2008-03-13 |
メルク エンド カムパニー インコーポレーテッド |
Ophthalmic composition for treating ocular hypertension
|
US7183310B2
(en)
|
2004-08-10 |
2007-02-27 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
SE0402029D0
(en)
*
|
2004-08-17 |
2004-08-17 |
Synphora Ab |
Prostaglandin and a derivative for the treatment of psoriasis
|
US9993558B2
(en)
|
2004-10-01 |
2018-06-12 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
US8541413B2
(en)
*
|
2004-10-01 |
2013-09-24 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
CA2583622A1
(en)
*
|
2004-10-13 |
2006-04-27 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US20080097108A1
(en)
*
|
2004-10-13 |
2008-04-24 |
Ying-Duo Gao |
Ophthalmic Compositions for Treating Ocular Hypertension
|
WO2006062839A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Alcon, Inc. |
Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
|
US7851504B2
(en)
|
2005-03-16 |
2010-12-14 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
US9241918B2
(en)
|
2005-03-16 |
2016-01-26 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
EP1864666B1
(en)
|
2005-03-31 |
2012-08-15 |
Asahi Glass Company, Limited |
Protective agent for retinal neuronal cell containing prostaglandin f2 alpha derivative as active ingredient
|
EP1870099A4
(en)
|
2005-04-13 |
2008-07-16 |
Ube Industries |
Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
|
US20060293378A1
(en)
*
|
2005-06-28 |
2006-12-28 |
Mcintire Gregory |
Method of lowering intraocular pressure
|
CA2613748A1
(en)
|
2005-06-29 |
2007-01-04 |
Pfizer Inc. |
Prostaglandin derivatives
|
JP2009502982A
(en)
*
|
2005-08-03 |
2009-01-29 |
メルク フロスト カナダ リミテツド |
EP4 receptor agonist, compositions and methods thereof
|
TW200744567A
(en)
*
|
2005-09-23 |
2007-12-16 |
Alcon Inc |
Phenylethylamine analogs and their use for treating glaucoma
|
DK1960353T3
(en)
|
2005-11-03 |
2014-05-26 |
Allergan Inc |
Prostaglandins and analogues as agents for lowering intraocular pressure
|
US20090062280A1
(en)
*
|
2006-03-13 |
2009-03-05 |
Doherty James B |
Ophthalmic Compositions for Treating Ocular Hypertension
|
CA2681668C
(en)
|
2006-03-23 |
2014-04-01 |
Michael S. Singer |
Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
|
JP2009541219A
(en)
*
|
2006-06-12 |
2009-11-26 |
メルク エンド カムパニー インコーポレーテッド |
Ophthalmic composition for the treatment of high intraocular pressure
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US7642370B2
(en)
|
2006-08-07 |
2010-01-05 |
Daiichi Fine Chemical Co., Ltd. |
Method for preparing prostaglandin derivative
|
EP2781505A1
(en)
|
2006-10-02 |
2014-09-24 |
Techfields Biochem Co. Ltd |
Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
|
WO2008041059A1
(en)
|
2006-10-03 |
2008-04-10 |
Techfields Biochem Co. Ltd |
Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
UY30883A1
(en)
|
2007-01-31 |
2008-05-31 |
Alcon Res |
PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
|
JPWO2008096804A1
(en)
|
2007-02-07 |
2010-05-27 |
テイカ製薬株式会社 |
Latanoprost-containing eye drops
|
US20090018204A1
(en)
*
|
2007-07-13 |
2009-01-15 |
Brinkenhoff Michael C |
Composition and method for enhancing hair growth
|
EP2077104A1
(en)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Micellar compositions with ophtalmic applications
|
US20090169629A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Micellar compositions with ophthalmic applications
|
EP2077105A1
(en)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Ophthalmic Micellar Compositions with Enhanced Stability
|
US20090170944A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Ophthalmic micellar compositions with enhanced stability
|
EP2135860A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Sandoz AG |
Improved process for the production of bimatoprost
|
EP2143712A1
(en)
|
2008-07-10 |
2010-01-13 |
Sandoz AG |
Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
US8722739B2
(en)
|
2008-10-29 |
2014-05-13 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
AU2009340420A1
(en)
|
2008-10-29 |
2010-08-26 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
US8623918B2
(en)
*
|
2008-10-29 |
2014-01-07 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
US20100204335A1
(en)
*
|
2008-12-01 |
2010-08-12 |
Allergan, Inc. |
Kit and composition for eyelash growth
|
IT1392492B1
(en)
|
2008-12-24 |
2012-03-09 |
Ind Chimica Srl |
PROCESS FOR THE PURIFICATION OF LATANOPROST, SYNTHETIC ANALOGUE OF PROSTAGLANDINA PGF2ALFA.
|
US20110293549A1
(en)
|
2009-02-03 |
2011-12-01 |
Athena Cosmetics, Inc. |
Composition, method and kit for enhancing hair
|
WO2010112615A1
(en)
|
2009-04-03 |
2010-10-07 |
Dsm Ip Assets B.V. |
Lysine derivatives functionalised with lipids
|
EP3354643B1
(en)
|
2009-05-01 |
2020-10-28 |
Aerie Pharmaceuticals, Inc. |
Dual mechanism inhibitors for the treatment of disease
|
US20120184552A1
(en)
|
2009-09-17 |
2012-07-19 |
Senju Pharmaceutical Co., Ltd. |
Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
|
US9149484B2
(en)
|
2009-11-09 |
2015-10-06 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
WO2011057129A2
(en)
|
2009-11-09 |
2011-05-12 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
PL2523669T3
(en)
*
|
2010-01-11 |
2017-06-30 |
Inotek Pharmaceuticals Corporation |
Combination, kit and method of reducing intraocular pressure
|
WO2011095990A2
(en)
|
2010-02-03 |
2011-08-11 |
Fdc Limited |
Process for the purification of prostaglandins and analogues thereof
|
EP2569325A4
(en)
|
2010-03-26 |
2013-10-09 |
Inotek Pharmaceuticals Corp |
Method of reducing intraocular pressure in humans using n6 - cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
|
BR112013001125A2
(en)
*
|
2010-07-19 |
2016-05-17 |
Inspire Pharmaceuticals Inc |
bifunctional rho kinase inhibiting compounds, composition and use
|
US9061034B2
(en)
|
2010-07-29 |
2015-06-23 |
Allergan, Inc. |
Preservative free bimatoprost and timolol solutions
|
EP2598118B1
(en)
|
2010-07-29 |
2018-09-05 |
Allergan, Inc. |
Preservative free bimatoprost and timolol solutions
|
JP2013534222A
(en)
|
2010-08-02 |
2013-09-02 |
ファーマ パテント ホールディング インコーポレイテッド |
Compositions, methods and kits for enhancing hair
|
JP2014500275A
(en)
|
2010-12-06 |
2014-01-09 |
フォリカ,インコーポレイテッド |
Methods for treating baldness and for promoting hair growth
|
WO2012099942A2
(en)
|
2011-01-19 |
2012-07-26 |
Terakine Therapeutics, Inc. |
Methods and compositions for treating metabolic syndrome
|
US8859616B2
(en)
|
2011-01-21 |
2014-10-14 |
Allergan, Inc. |
Compounds and methods for enhancing hair growth
|
TW202126308A
(en)
|
2011-02-04 |
2021-07-16 |
日商興和股份有限公司 |
Drug therapy for preventing or treating glaucoma
|
EP2495235B1
(en)
|
2011-03-04 |
2015-08-05 |
Newchem S.p.A. |
Process for the synthesis of prostaglandins and intermediates thereof
|
CN102690219A
(en)
*
|
2011-03-24 |
2012-09-26 |
天津信汇制药股份有限公司 |
Method for purifying bimatoprost
|
US8715713B2
(en)
|
2011-04-29 |
2014-05-06 |
Allergan, Inc. |
Solvent cast film sustained release latanoprost implant
|
CA3094762C
(en)
*
|
2011-06-02 |
2023-09-26 |
CHINOIN Zrt. |
Novel processes for the preparation of prostaglandin amides
|
US8426471B1
(en)
|
2011-12-19 |
2013-04-23 |
Topokine Therapeutics, Inc. |
Methods and compositions for reducing body fat and adipocytes
|
MX2014009086A
(en)
|
2012-01-26 |
2015-06-05 |
Inotek Pharmaceuticals Corp |
Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h- purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof.
|
WO2013133730A1
(en)
*
|
2012-03-09 |
2013-09-12 |
Instytut Farmaceutyczny |
PROCESS FOR PREPARATION OF PROSTAGLANDIN F2α ANALOGUES
|
JP5877620B2
(en)
|
2012-11-21 |
2016-03-08 |
トポカイン セラピューティックス, インコーポレイテッド |
Methods and compositions for locally increasing body fat
|
US9120738B2
(en)
*
|
2012-12-28 |
2015-09-01 |
Allergan, Inc. |
Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
|
CN109602691A
(en)
|
2013-02-15 |
2019-04-12 |
阿勒根公司 |
Sustained drug delivery implantation material
|
AU2014239222A1
(en)
|
2013-03-15 |
2015-10-01 |
Inotek Pharmaceuticals Corporation |
Ophthalmic formulations
|
HUE061618T2
(en)
|
2013-03-15 |
2023-07-28 |
Aerie Pharmaceuticals Inc |
Compound for use in the treatment of ocular disorders
|
NO2753788T3
(en)
|
2013-05-10 |
2018-06-16 |
|
|
US9820993B2
(en)
|
2013-05-15 |
2017-11-21 |
Topokine Therapeutics, Inc. |
Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
|
ITMI20132193A1
(en)
*
|
2013-12-23 |
2015-06-24 |
Ind Chimica Srl |
MICROBIOLOGICAL PROCESS FOR THE PREPARATION OF USEFUL INTERMEDIATES IN THE SYNTHESIS OF PROSTAGLANDINE
|
HU231214B1
(en)
*
|
2014-03-13 |
2021-11-29 |
CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. |
New process for preparing high purity prostaglandins
|
US10188661B2
(en)
|
2014-06-27 |
2019-01-29 |
Topokine Therapeutics, Inc. |
Topical dosage regimen
|
WO2016063184A1
(en)
|
2014-10-20 |
2016-04-28 |
Sentiss Pharma Private Limited |
Ophthalmic solution
|
CN107645951B
(en)
|
2014-11-25 |
2021-05-04 |
艾克思摩尔有限公司 |
Compositions and methods for delivering one or more bioactive agents
|
WO2017054009A1
(en)
|
2015-09-27 |
2017-03-30 |
Follica, Inc. |
Needling device and drug applicator
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
MX2019002396A
(en)
|
2016-08-31 |
2019-07-08 |
Aerie Pharmaceuticals Inc |
Ophthalmic compositions.
|
CA3057872A1
(en)
|
2017-03-31 |
2018-10-04 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
AU2019337703B2
(en)
|
2018-09-14 |
2023-02-02 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
CN112142703A
(en)
*
|
2020-09-30 |
2020-12-29 |
东北制药集团股份有限公司 |
Carprostenol tromethamine related impurity L-butyl 15-ketone and preparation method thereof
|